Inhaltsbereich
| 23 Einträge | 1, 2 › » |
Seite 1 / 2
 Druckansicht
|
| eIF3 controls cell size independently of S6K1-activity. |
| Schipany K, Rosner M, Ionce L, Hengstschläger M, Kovacic B |
| Oncotarget. 2015 Jun 29. pii: 4458 |
| PMID: 26172298 |
| Clinical impact of studying epithelial-mesenchymal plasticity in pluripotent stem cells. |
| Kovacic B, Rosner M, Schipany K, Ionce L, Hengstschläger M |
| European journal of clinical investigation. 2015 Mar 30. doi: 10.1111/eci.12415 |
| PMID: 25646864 |
| Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. |
| Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V |
| Leukemia. 2014 May 5. pii: leu2014152. doi: 10.1038/leu.2014.152. pmc: PMC4158830 |
| PMID: 24791858 |
| The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. |
| Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O, Moritz N, Hoelbl A, Kovacic B, Freissmuth M, Müller M, Villunger A, Müllauer L, Schmatz AI, Streubel B, Porpaczy E, Jäger U, Stoiber D, Sexl V |
| Blood. 2011 Aug 30. pii: blood-2010-10-313098. doi: 10.1182/blood-2010-10-313098 |
| PMID: 21878673 |
| Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. |
| Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V |
| EMBO molecular medicine. 2010 Mar 11. doi: 10.1002/emmm.201000062. pmc: PMC2906698. mid: UKMS30451 |
| PMID: 20201032 |
| STAT1 acts as a tumor promoter for leukemia development. |
| Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, Sexl V |
| Cancer cell. 2006 Jul 17. pii: S1535-6108(06)00182-6. doi: 10.1016/j.ccr.2006.05.025 |
| PMID: 16843267 |
| Clusterin regulates drug-resistance in melanoma cells. |
| Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wacheck V, Gleave ME, Pehamberger H, Jansen B |
| The Journal of investigative dermatology. 2005 Jun 15. pii: JID23720. doi: 10.1111/j.0022-202X.2005.23720.x |
| PMID: 15955107 |
| TYK2 is a key regulator of the surveillance of B lymphoid tumors. |
| Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz E, Artwohl M, Kleine OC, Muller M, Baumgartner-Parzer S, Ghysdael J, Freissmuth M, Sexl V |
| The Journal of clinical investigation. 2004 Dec 3. doi: 10.1172/JCI22315. pmc: PMC529282 |
| PMID: 15578097 |
| Full biological characterization of human pluripotent stem cells will open the door to translational research. |
| Kramer N, Rosner M, Kovacic B, Hengstschläger M |
| Archives of toxicology. 2016 Jun 21. doi: 10.1007/s00204-016-1763-2. pii: 10.1007/s00204-016-1763-2 |
| PMID: 27325309 |
| Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. |
| Linke M, Pham HT, Katholnig K, Schnöller T, Miller A, Demel F, Schütz B, Rosner M, Kovacic B, Sukhbaatar N, Niederreiter B, Blüml S, Kuess P, Sexl V, Müller M, Mikula M, Weckwerth W, Haschemi A, Susani M, Hengstschläger M, Gambello MJ, Weichhart T |
| Nature immunology. 2017 Jan 16. pii: ni.3655. doi: 10.1038/ni.3655 |
| PMID: 28092373 |
| CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. |
| Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zöchbauer-Müller S, Zuber J, Malumbres M, Kollmann K, Sexl V |
| Blood. 2014 Oct 23. pii: blood-2014-06-584417. doi: 10.1182/blood-2014-06-584417. pmc: PMC4281832 |
| PMID: 25342715 |
| Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. |
| Putz EM, Hoelzl MA, Baeck J, Bago-Horvath Z, Schuster C, Reichholf B, Kern D, Aberger F, Sexl V, Hoelbl-Kovacic A |
| Cancers. 2014 Jan 27. pii: cancers6010193. doi: 10.3390/cancers6010193. pmc: PMC3980609 |
| PMID: 24473086 |
| PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. |
| Berger A, Hoelbl-Kovacic A, Bourgeais J, Hoefling L, Warsch W, Grundschober E, Uras IZ, Menzl I, Putz EM, Hoermann G, Schuster C, Fajmann S, Leitner E, Kubicek S, Moriggl R, Gouilleux F, Sexl V |
| Leukemia. 2013 Nov 22. pii: leu2013351. doi: 10.1038/leu.2013.351. pmc: PMC3948164 |
| PMID: 24263804 |
| Identification of CD25 as STAT5-Dependent Growth-Regulator of Leukemic Stem Cells in Ph+ CML. |
| Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzl G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Nov 25. pii: 1078-0432.CCR-15-0767. doi: 10.1158/1078-0432.CCR-15-0767 |
| PMID: 26607600 |
| Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. |
| Farhan S, Baber U, Vogel B, Aquino M, Chandrasekhar J, Faggioni M, Giustino G, Kautzky-Willer A, Sweeny J, Shah S, Vijay P, Barman N, Moreno P, Kovacic J, Dangas G, Kini A, Mehran R, Sharma S |
| The American journal of cardiology. 2017 Jan 25. pii: S0002-9149(17)30063-2. doi: 10.1016/j.amjcard.2016.12.035 |
| PMID: 28236457 |
| Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. |
| Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V |
| Blood. 2018 Jun 14. pii: blood-2017-10-810739. doi: 10.1182/blood-2017-10-810739 |
| PMID: 29907599 |
| Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. |
| Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, Huuhtanen J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, Sexl V |
| Leukemia. 2019 Jan 24. doi: 10.1038/s41375-018-0369-5. pii: 10.1038/s41375-018-0369-5 |
| PMID: 30679796 |
| High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. |
| Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R |
| Haematologica. 2019 May 23. pii: haematol.2019.216986. doi: 10.3324/haematol.2019.216986 |
| PMID: 31123029 |
| A kinase-independent role for CDK8 in BCR-ABL1 leukemia. |
| Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, Liang Y, Kwiatkowski NP, Fux D, Hoelbl-Kovacic A, Kubicek S, Melo JV, Valent P, Weichhart T, Grebien F, Zuber J, Gray NS, Sexl V |
| Nature communications. 2019 Oct 18. doi: 10.1038/s41467-019-12656-x. pii: 10.1038/s41467-019-12656-x |
| PMID: 31628323 |
| All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia. |
| Nguyen CH, Bauer K, Hackl H, Schlerka A, Koller E, Hladik A, Stoiber D, Zuber J, Staber PB, Hoelbl-Kovacic A, Purton LE, Grebien F, Wieser R |
| Cell death & disease. 2019 Dec 10. doi: 10.1038/s41419-019-2172-2. pii: 10.1038/s41419-019-2172-2 |
| PMID: 31822659 |
| 23 Einträge | 1, 2 › » |
Seite 1 / 2
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
